Yuan Yuan, M.D., Ph.D.
Medical Oncologist
4.7 (182 RATINGS)
Clinical Expertise
Breast Cancer
Triple-Negative Breast Cancer
Breast Cancer Immunotherapy
Adoptive Cell Therapy in Breast Cancer
Research Area
Breast Cancer Research
Breast Cancer Immunotherapy
Adoptive Cell Therapy in Breast Cancer
Triple-Negative Breast Cancer
Languages
Appointments
Associate Professor, Department of Medical Oncology & Therapeutics Research
Clinical Teams
Research Teams
Yuan Yuan, M.D., Ph.D., is an associate professor specializing in breast medical oncology in the Department of Medical Oncology & Therapeutics Research.
Dr Yuan’s research focuses on translational and clinical studies investigating novel therapeutics inmetastatic breast cancer, including novel targeted therapy, immunotherapy combinations, adoptive cell therapy and oncolytic virus therapy. She is an active member of the immunotherapy modality team at City of Hope.
She has successfully developed and completed many investigator initiated breast cancerimmune therapy studies including a Phase 1/2 trial combining letrozole, palbociclib andpembrolizumab in patients with HR+ metastatic breast cancer (NCT02778685); a Phase 1/2 trial androgen receptor targeted therapy GTx-024 in combination with pembrolizumab in patientswith metastatic AR+ triple-negative breast cancer (NCT02971761) and a Phase 1B study combining ipatasertib with carboplatin or carboplatin/paclitaxel or capecitabine/atezolizumab in patients withmetastatic triple-negative breast cancer (NCT03853707).
Her recent research interest has beenfocusing on adoptive cell therapy for breast cancer. She is the principal investigator for multiple CAR T and NK cell therapy trials: HER2-targeted dual switch CAR T therapy in HER+ cancer(NCT046504751); Safety and efficacy of SNK01 in combination with trastuzumab or cetuximab insubjects with advanced HER2 or EGFR cancers (NCT04464967).
She is the institutional principal investigator of the I-SPY2 trial, a groundbreaking basket trial of neoadjuvant treatment for locally advanced breast cancer. She is working closely with world-renowned researchers in immunoncology and adoptive cell therapy in developing novel immune and cell therapies in breast cancer. Her work has been funded by the STOP Cancer Foundation, National Institutes of Health and the Department of Defense.
2009-present, American Board of Hematology
2009-present, American Board of Oncology
2006-present, American Board of Internal Medicine
1997-2002, Ph.D., Biochemistry and Molecular Biology, University of California Riverside, Riverside, CA
1994-1997, M.S., Oncology, Peking Union Medical College, Beijing, China
1989-1994, Bachelor of Medicine, Xu-Zhou Medical College, Xu-Zhou, China
2006-2009, Research Fellowship, Scripps Research Institute, La Jolla, CA
2006-2009, Fellowship in Hematology and Oncology, New York University Medical Center, under the direction of Dr. Franco Muggia
2004-2006, Residency, Internal Medicine, New York University Downtown Hospital in New York, NY
2003-2004, Internship, Internal Medicine, Affiliated Hospital of Xu-Zhou Medical College, Xu-Zhou, China
2003-2004, Internship, Internal Medicine, New York University Downtown Hospital in New York, NY
2018-present, Associate Professor, Department of Medical Oncology & Therapeutics Research, City of Hope, Duarte, CA
2012-2017, Assistant Professor, Department of Medical Oncology & Therapeutics Research, City of Hope, Duarte, CA
2009-2012, Assistant Professor, Division of Medical Oncology and Hematology, Loma Linda University , CA
2002-2003, Postdoctoral Research Assistant, The Scripps Institute, La Jolla, CA
1994-1997, Research Assistant, Cancer Institute, Peking Union Medical College, Beijing, China
- Collaborating with cancer biologist in developing translational projects in understanding mechanisms of endocrine resistance
- Preclinical studies of novel combination strategies of targeted therapies such as combinations of PI3K inhibitors and CDK4/6 inhibitors
- Developing therapeutic clinical trial targeting endocrine resistant breast cancers
- Biomarker research in breast cancer early detection
American Society of Hematology
American Society of Clinical Oncology
Southwest Oncology Group
SWOG Breast Committee
Cancer Trials Support Unit
- Yuan Y, Yost S, Bitar J-S, et al. Phase I/II Trial of Palbociclib, Pembrolizumab, and Letrozole in Patients with Hormone Receptor Positive Metastatic Breast Cancer. European Journal of Cancer (Accepted 06/2021)
- Yuan Y, Lee JS, Yost SE, Stiller T, Blanchard MS, Padam S, Katheria V, Kim H, Sun C, Tang A, Martinez N. Phase II study of neratinib in older adults with HER2 amplified or HER2/3 mutated metastatic breast cancer. Journal of geriatric oncology. 2021 Jun 1;12(5):752-8.
- O'Shaughnessy J, Kaklamani VG, Yuan Y, Barone J, Diab S, Crozier JA, Whitworth PW, Tedesco KL, Maganini R, Rahman10 RL, Encarnacion11 CA. Molecular profiles of genomically high risk ER+ HER2-breast cancer tumors classified as functionally basal or luminal B by the 80-gene signature.
- Yuan Y, Yost SE, Frankel PH, Ruel C, Murga M, Tang A, Martinez N, Waisman JR, Stewart DB, Patel NH, Mortimer JE. A phase I/IB study of ipatasertib in combination with carboplatin or carboplatin/paclitaxel or capecitabine and atezolizumab in patients with metastatic triple-negative breast cancer.
- Yuan Y, Pan K, Mortimer J, Chlebowski RT, Luo J, Yan JE, Yost SE, Kroenke CH, Adams‐Campbell L, Nassir R, Sun Y. Metabolic syndrome risk components and mortality after triple‐negative breast cancer diagnosis in postmenopausal women in the Women's Health Initiative. Cancer. 2021 May 15;127(10):1658-67.
- Wong CW, Yost SE, Lee JS, Gillece JD, Folkerts M, Reining L, Highlander SK, Eftekhari Z, Mortimer J, Yuan Y. Analysis of Gut Microbiome Using Explainable Machine Learning Predicts Risk of Diarrhea Associated With Tyrosine Kinase Inhibitor Neratinib: A Pilot Study. Frontiers in oncology. 2021 Mar 10;11:283.
- Yuan Y, Lee JS, Yost SE, Li SM, Frankel PH, Ruel C, Schmolze D, Robinson K, Tang A, Martinez N, Stewart D. Phase II Trial of Neoadjuvant Carboplatin and Nab‐Paclitaxel in Patients with Triple‐Negative Breast Cancer. The oncologist. 2021 Mar;26(3):e382-93.
- Hobbs E, Lindquist E, Sullivan B, Yoon E, Yuan Y, Marx A, Willey J, Sun H, Layman R, Stover D, Yuan Y. Neratinib and tepotinib combination in advanced breast cancer and inflammatory breast cancer patients with abnormal HER2 and c-Met pathway activity as measured by the CELsignia signaling pathway activity test. In CANCER RESEARCH 2021 Feb 1 (Vol. 81, No. 4). 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA: AMER ASSOC CANCER RESEARCH.
- Tolaney S, Kalinsky K, Kaklamani V, D’Adamo D, Aklan G, Tsai M, O’Regan R, Kaufman P, Wilks S, Andreopoulou E, Patt D, Yuan Y, Wang G, Savulsky C, Xing D, Kleynerman E, Karantza V, Diab S. Eribulin Plus Pembrolizumab in Patients with Metastatic Triple-Negative Breast Cancer. (ENHANCE 1): A Phase 1b/2 study. Clin Cancer Res. 2021 Mar 16. doi: 10.1158/1078-0432.CCR-20-4726. PMID: 33727258.
- Lee J, Yost S, Yuan Y. Case Report: Significant Response to the Combination of Lenvatinib and Immune Checkpoint Inhibitor in a Patient with Heavily Pretreated Metastatic Triple Negative Breast Cancer. Front Oncol. 2021 Jan 11;10:582185. doi: 10.3389/fonc.2020.582185. PMID: 33505906.
- Wortman J, He T-F, Rosario A, Wang R, Schmolze D, Yuan Y, Yost S, Li X, Levine H, Atwal G, Lee P, Yu C. Occupancy and Fractal Dimension Analyses of the Spatial Distribution of Cytotoxic (CD8 ) T Cells Infiltrating the Tumor Microenvironment in Triple Negative Breast Cancer. Biophysical Reviews and Letters Vol. 15, No. 2 (2020 June 25) 83–98.
- Yu G, Li X, He T-F, Gruosso T, Zuo D, Souleimanova M, Ramos V, Omeroglu A, Meterissian S, Guoit M-C, Yang L, Yuan Y, Oark M, Lee P, Levine H. Predicting Relapse in Patients with Triple Negative Breast Cancer (TNBC) Using a Deep-Learning Approach. Front Physiol. 2020 Sep 23;11:511071. doi: 10.3389/ fphys.2020.511071. PMID: 33071806.
- Egelston C, Guo W, Yost S, Lee JS, Rose D, Avalos C ... Yuan Y. (2021). Pre-existing effector T-cell levels and augmented myeloid cell composition denote response to CDK4/6 inhibitor palbociclib and pembrolizumab in hormone receptor-positive metastatic breast cancer. Journal for immunotherapy of cancer, 9(3).
- Griffiths JI, Chen J, Winblad O, O’Dea A, Sharma P, Trivedi M, Kalinsky K, Wisinski KB, O’Regan R, Makhoul I, Yuan Y. Reconstructing tumor trajectories during therapy through integration of multiple measurement modalities. bioRxiv. 2021 Jan 1.
- Clare CY, Wortman JC, He TF, Solomon S, Zhang RZ, Rosario A, Wang R, Tu T, Schmolze D, Yuan Y, Yost SE. Physics Approaches to the Spatial Distribution of Immune Cells in Tumors. Reports on Progress in Physics. 2020 Nov 24.
- Yuan Y, Lee JS, Yost SE, Frankel PH, Ruel C, Egelston CA, Guo W, Gillece JD, Folkerts M, Reining L, Highlander SK. A Phase II Clinical Trial of Pembrolizumab and Enobosarm in Patients with Androgen Receptor‐Positive Metastatic Triple‐Negative Breast Cancer. The Oncologist. 2020 Nov 3.
- Yu C, Wortman J, He T-F, Solomon S, Zhang R, Rosario A, Wang R, Tu T, Schmolze D, Yuan Y, Yost S, Li X, Levine H, Atwal G, Lee P. Physics Approaches to the Spatial Distribution of Immune Cells in Tumors. Reports on Progress in Physics. Rep Prog Phys. 2021 Feb;84(2):022601. doiL10.1088/1361-6633/abcd7b. PMID: 33232952.
- Solomon I, McGraw S, Shen J, Albayrak A, Yuan Y. Engaging Patients in Precision Oncology: Development and Usability of a Web-Based Patient-Facing Genomic Sequencing Report. JCO Precision Oncology. 2020 Apr 14;4:PO.19.00195. doi: 10.1200/PO.19.00195. PMID: 32923887.
- Mortimer J, Kruper L, Cianfrocca M, Lavasani S, Liu S, Tank-Patel N, Sedrak M, Smith W, Stewart D, Waisman J, Yeon C, Wang T, Yuan Y. Use of HER2 Directed Therapy in Metastatic Breast Cancer and How Community Physicians Collaborate to Improve Care. Journal of Clinical Medicine. Manuscript ID: jcm-811349. J Clin Med 2020 Jun 24;9(6):e1984. doi: 10.3390/jcm9061984. PMID:32599960.
- Lee J, Yost S, Yuan Y. Neoadjuvant Treatment for Triple Negative Breast Cancer: Recent Progresses and Challenges. Cancers. Manuscript ID: cancers-808175. Cancers (Basel). 2020 May 29;12(6):e1404. doi: 10.3390/cancers12061404. PMID: 32486021.
- Liu J, Gutierrez E, Tiwari A, Padam S, Li D, Dale W, Pal S, Stewart D, Subbiah S, Bosserman L, Presant C, Phillips T, Yap K, Hill A, Bhatt G, Yeon C, Cianfrocca M, Yuan Y, Mortimer J, Sedrak M. Strategies to Improve Participation of Older Adults in Cancer Research: Strengthening Collaboration Between Academic and Community-based Practices. Journal of Clinical Medicine. Manuscript ID: jcm-792244. J Clin Med. 2020 May 22;9(5):1571. doi: 10.3390/jcm9051571. PMID: 32455877.
- He T, Yost S, Frankel P, Dagis A, Yu C, Wang R, Rosario A, Tu T, Solomon S, Schmolze D, Mortimer J, Lee P, Yuan Y. Multi-Panel Immunofluorescence Analysis of Tumor Infiltrating Lymphocytes in Triple Negative Breast Cancer: Evolution of Tumor Immune Profiles and Patient Prognosis. PLoS One. 2020 Mar 9;15(3)e0229955. doi: 10.1371/journal.pone.0229955. PMID: 32150594.
Ratings and reviews below are gathered from the Press Ganey Clinician and Group Consumer Assessment of Healthcare Providers and Systems (CG CAHPS) survey. CG CAHPS is a standardized survey that is used to measure a patient's experience in the physician office setting. Ratings are an average of all responses to questions about a provider's care, with 5 stars being the highest.
Ratings
4.8
Know important info medical history
4.8
Show respect for what you say
4.8
Provider explain in way you understand
4.7
Rate provider 0-10
4.7
Recommend this provider office
4.7
Provider listen carefully to you
4.6
Spend enough time with you
Reviews
03/30/22
Dr. Yuan is amazing. She is so personable & easy to talk to about medical issues or just catching up on life. She puts me at ease, answers any of my concerns, offers me options and I always feel I'm under great care under her guidance. - Verified patient
03/30/22
COH staff are professional, courteous & wonderful. I always highly recommended & compliment them when talking with friends. [...] - Verified patient
01/31/22
Always have a very warm, caring and friendly encounters/experience with all of the COH staff (doctors, nurses, receptionists, techs) and going through every chemo treatment, radiation, labs and ff up visits made it easier to deal with by being surrounded with all these caring people who gives you/us a warm smile and encouragement to get better. - Verified patient
01/31/22
Thank you for all you do! Dr. Yuan is very thorough with explaining procedures, treatments, and [...], NP (risks and side effects and always asks about any concerns/questions I have to make sure I am comfortable and understand what is being done. Thank you so much for all you do. - Verified patient
01/13/22
I am very fortunate to be a patient of Dr. Yuan and all City of Hope staff. - Verified patient